

NCIC CLINICAL TRIALS GROUP

GENITOURINARY

DISEASE SITE COMMITTEE MEETING AGENDA

DELTA CHELSEA HOTEL, TORONTO, ON

ROOM: Rossetti

APRIL 30, 2011 – 9:00 AM – 03:30 PM

CHAIR: F. SAAD

(03:30 PM – 04:30 PM EXECUTIVE COMMITTEE MEETING – CLOSED)

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- *To understand and address, through clinical and translational research, the disease burden associated with genitourinary malignancies in Canada.*
- *To review recent developments in the understanding of molecular biology and new therapeutics as these relate to genitourinary malignancies.*
- *To update, review, and discuss recent results of clinical studies conducted by or in collaboration with NCIC Clinical Trials Group.*
- *To provide a learning environment supportive to new investigators.*
- *To understand and apply new clinical trial methodologies in the field of clinical research related to genitourinary malignancies.*

| | | |
|-----------------|---|-----------------------|
| 9:00 am | WELCOME AND APPROVAL OF PREVIOUS MINUTES | F. Saad |
| 9:10 am | SPRING MEETING CME ACCREDITATION | W. Parulekar |
| 9:20 am | NCIC CTG/INTERGROUP PHASE III TRIALS: OPEN | |
| | PR.11 | L. Klotz |
| | PR.13 (RADICALS)/MRC PR.10 | C. Catton/F. Saad |
| 10:00 am | NCIC CTG/INTERGROUP PHASE III TRIALS: CLOSED. PENDING ANALYSES | |
| | PR.3 | P. Warde/ M. Brundage |
| | PR.8/SWOG 9346 | B. Donnelly |
| | BL 8/EORTC 30994 | L. Wood |
| | REC.2/ECOG E2805 Sunitinib/placebo vs. Sorafenib/placebo vs. placebo in resected RCC | M. Jewett/ L. Wood |
| 10:15 am | COFFEE BREAK | |

continued on next page ...

- 10:30 am NCIC CTG PHASE III TRIALS: RECENT ANALYSES**
 PR.7 J. Crook/ L. Klotz/ C. O'Callaghan
- 10:45 am CTSU TRIALS ACTIVATED BY NCIC CTG: OPEN**
 PRC.2/CALGB 90202 Early Versus Standard Zoledronic Acid
 in CaP metastatic to bone F. Saad
 PRC.3/CALGB 90203 Neoadjuvant Docetaxel plus Androgen
 Deprivation prior to RP v.s. RP only M.Gleave/W. Parulekar
- 11:00 am NCIC CTG IND TRIALS**
 IND.195: A Phase II Study of SB 939 in Patients with CRPC B. Eigl/K. Chi
- 11:10 am OPEN CUOG TRIALS**
- 11:30 am NEW TRIAL PROPOSALS**
 Phase III Study of HDR Brachytherapy in Intermediate Risk CaP E. Vigneault/ A. Loblaw
- 12:00 pm Lunch**
- 1:30 pm UPDATE ON CLOSED CUOG TRIALS**
- 2:00 pm DOG REPORTS**
 Localized Prostate Cancer A. Loblaw/ N. Fleshner
 Advanced Prostate Cancer K. Chi/ F. Saad
 Advanced Bladder W. Kassouf/ S. North
 Renal J. Knox/ A. Kapoor
 Testes C. Kollaansberger/ P. Chung
 Superficial bladder A. So
- 3:10 pm OPEN DISCUSSION: NEW BUSINESS, STRATEGIC PLANNING**
- 3:30 pm Meeting Adjourned, EXECUTIVE COMMITTEE MEETING TO FOLLOW (CLOSED)**